Publications for Anders Olsson
Co-author map based on ISI articles 2007-
Publications mentioned in social media 127 times*
Journal Articles
Robert L. Ohsfeldt, Anders G Olsson, Marie M. Jensen, Sanjay K. Gandhi and Thomas Paulsson
Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the Jupiter trial
Journal of Media Economics, 2012, 15(1), 125-133.
|
Sanya K. Gandhi, Marie M. Jensen, Kathleen M. Fox, Lee Smolen, Anders Olsson and Thomas Paulsson
Cost-effectiveness of resuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
ClinicoEconomics and Outcomes Research, 2012, 4, 1-11.
|
David Sullivan, Anders Olsson, Rob Scott, Jae B Kim, Allen Xue, Val Gebski, Scott M Wasserman and Evan A Stein
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients The GAUSS Randomized Trial
Journal of the American Medical Association (JAMA), 2012, 308(23), 2497-2506.
Web of Science® Times Cited: 7 |
Gregory G Schwartz, Anders Olsson, Markus Abt, Christie M Ballantyne, Philip J Barter, Jochen Brumm, Bernard R Chaitman, Ingar M Holme, David Kallend, Lawrence A Leiter, Eran Leitersdorf, John J V McMurray, Hardi Mundl, Stephen J Nicholls, Prediman K Shah, Jean-Claude Tardif and R Scott Wright
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
New England Journal of Medicine, 2012, 367(22), 2089-2099.
Web of Science® Times Cited: 11 |
Darbie L Maccubbin, Fabian Chen, Jennifer Weimer Anderson, Waheeda Sirah, Christine McCrary Sisk, Uma Kher, Anders Olsson, Harold E Bays and Yale B Mitchel
Effectiveness and Safety of Laropiprant on Niacin-Induced Flushing
American Journal of Cardiology, 2012, 110(6), 817-822.
Web of Science® Times Cited: 3 |
Sung Kee Ryu, Ziad Mallat, Joelle Benessiano, Alain Tedgui, Anders Olsson, Weihang Bao, Gregory G Schwartz and Sotirios Tsimikas
Phospholipase A(2) Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes
Circulation, 2012, 125(6), 757-U71.
Web of Science® Times Cited: 7 |
Anders G. Olsson
Diskussionen om vad som ska vara målet för lipidsänkning fortsätter: Expertrådet - en stoppkloss för modern kardiovaskulär prevention: [The discussion on target goals in lipid reduction is still going on. The expert committee - a block for current cardiovascular prevention]
Läkartidningen, 2011, 108(47), 2443.
|
Anders G. Olsson
Målvärden för LDL-kolesterol har satts ur spel. Kolesterolet bör sänkas maximalt vid hög kardiovaskulär risk: [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk]
Läkartidningen, 2011, 108(22-23), 1240-1243.
|
Anders G Olsson
Statin efter intracerebral blödning bör ifrågasättas: Subgruppsanalyser visar på ökad risk för ny blödning
Läkartidningen, 2011, 108(24-25), 1297-1298.
|
Anders Olsson, Christina Lindahl, Ingar Holme, Rana Fayyad, Ole Faergeman, John J P Kastelein, Matti J Tikkanen, Mogens Lytken Larsen and Terje R Pedersen
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION and REHABILITATION, 2011, 18(2), 262-269.
Web of Science® Times Cited: 2 |
Anders G Olsson
HDL and LDL as therapeutic targets for cardiovascular disease prevention: The possible role of niacin
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2010, 20(8), 553-557.
Web of Science® Times Cited: 2 |
Anders Olsson, Finn Bengtsson, A. Rosengren and P. Tornvall
Patienten framför allt!
Läkartidningen, 2010, 107(24), 1639.
|
Terje R Pedersen, Nilo B Cater, Ole Faergeman, John J P Kastelein, Anders Olsson, Matti J Tikkanen, Ingar Holme, Mogens Lytken Larsen, Christina Lindahl and Michael Szarek
Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)
AMERICAN JOURNAL OF CARDIOLOGY, 2010, 106(3), 354-359.
Web of Science® Times Cited: 9 |
Anders Olsson
Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease
Expert Opinion on Pharmacotherapy, 2010, 11(10), 1715-1726.
Web of Science® Times Cited: 7 |
Anders Olsson, Finn Bengtsson, A. Rosengren and P. Tornvall
Kolesterolhypotesen står sig
Läkartidningen, 2010, 107(12), 831-836.
|
I Holme, R Fayyad, O Faergeman, J J P Kastelein, Anders Olsson, M J Tikkanen, M L Larsen, C Lindahl, H Holdaas and T R Pedersen
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial
JOURNAL OF INTERNAL MEDICINE, 2010, 267(6), 567-575.
Web of Science® Times Cited: 4 |
Paul W Ladenson, Jens D Kristensen, E Chester Ridgway, Anders Olsson, Bo Carlsson, Irwin Klein, John D Baxter and Bo Angelin
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362(10), 906-916.
Web of Science® Times Cited: 81 |
Anders G Olsson
JUPITER-studien lyfter fram primärprevention
Läkartidningen, 2009, 106(23), 1577.
|
Anders G Olsson
Livsstilsförändring och läkemedel kompletterar varandra
Läkartidningen, 2009, 106(34), 2069.
|
Anders G Olsson
Slutrunda om statiner: Faktum kvarstår att 80 mg simvastatin dagligen ger hög myopatirisk
Läkartidningen, 2009, 106(43), 2783-4; author reply 2784.
|
Anders Olsson
Faktum kvarstår att 80 mg simvastatin dagligen ger hög myopatirisk
Läkartidningen, 2009, 106(43), 2783.
|
Anders Olsson
Varning för simvastatin 80 mg!
Läkartidningen, 2009, 106(40), 2549-2550.
|
Gregory G Schwartz, Anders Olsson, Christie M Ballantyne, Phillip J Barter, Ingar M Holme, David Kallend, Lawrence A Leiter, Eran Leitersdorf, John J V McMurray, Prediman K Shah, Jean-Claude Tardif, Bernard R Chaitman, Regina Duttlinger-Maddux and John Mathieson
Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
American Heart Journal, 2009, 158(6), 896-U34.
Web of Science® Times Cited: 82 |
Matti J Tikkanen, Michael Szarek, Rana Fayyad, Ingar Holme, Nilo B Cater, Ole Faergeman, John J P Kastelein, Anders Olsson, Mogens Lytken Larsen, Christina Lindahl and Terje R Pedersen
Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy Insights From the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Trial
Journal of the American College of Cardiology, 2009, 54(25), 2353-2357.
Web of Science® Times Cited: 21 |
Scott Kinlay, Gregory G Schwartz, Anders Olsson, Nader Rifai, Weihang Bao, Peter Libby and Peter Ganz
Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study
Atherosclerosis, 2009, 206(2), 551-555.
Web of Science® Times Cited: 4 |
Anders Olsson and P.M. Nilsson
"The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice ["Ju lägre LDL-kolesterol, desto bättre" gäller fortsatt Negativa/neutrala slutsatser av tre statinstudier ändrar inte klinisk praxis.]
Läkartidningen, 2009, 106(12), 854-857.
|
Anders Olsson
JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor [JUPITER kan ge paradigmskifte i prevention av hjärt-kärlsjukdom. Fokus på inflammation som riskfaktor.]
Läkartidningen, 2009, 106(21-22), 1471-1475.
|
Ole Faergeman, Ingar Holme, Rana Fayyad, Sonal Bhatia, Scott M Grundy, John J P Kastelein, John C LaRosa, Mogens Lytken Larsen, Christina Lindahl, Anders G Olsson, Matti J Tikkanen, David D Waters and Terje R Pedersen
Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease
AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104(4), 459-463.
Web of Science® Times Cited: 27 |
Ingar Holme, Timo E Strandberg, Ole Faergeman, John J P Kastelein, Anders Olsson, Matti J Tikkanen, Mogens Lytken Larsen, Christina Lindahl and Terje R Pedersen
Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)
ATHEROSCLEROSIS, 2009, 205(2), 522-527.
Web of Science® Times Cited: 5 |
Anders G Olsson
Lipid lowering and aortic valve disease
CURRENT ATHEROSCLEROSIS REPORTS, 2009, 11(5), 377-383.
Web of Science® Times Cited: 1 |
Ingar Holme, Michael Szarek, Nilo B Cater, Ole Faergeman, John J P Kastelein, Anders Olsson, Matti J Tikkanen, Mogens Lytken Larsen, Christina Lindahl and Terje R Pedersen
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION and REHABILITATION, 2009, 16(3), 315-320.
Web of Science® Times Cited: 7 |
Alexander E Fraley, Gregory G Schwartz, Anders Olsson, Scott Kinlay, Michael Szarek, Nader Rifai, Peter Libby, Peter Ganz, Joseph L Witztum and Sotirios Tsimikas
Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low- Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes Results From the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) Trial
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53(23), 2186-2196.
Web of Science® Times Cited: 24 |
Timo E Strandberg, Ingar Holme, Ole Faergeman, John J P Kastelein, Christina Lindahl, Mogens Lytken Larsen, Anders Olsson, Terje R Pedersen and Matti J Tikkanen
Comparative Effect of Atorvastatin (80 mg) Versus Simvastatin (20 to 40 mg) in Preventing Hospitalizations for Heart Failure in Patients With Previous Myocardial Infarction
AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103(10), 1381-1385.
Web of Science® Times Cited: 5 |
M.J. Tikkanen, I. Holme, N.B. Cater, M. Szarek, O. Faergeman, J.J.P. Kastelein, Anders Olsson, M.L. Larsen, C. Lindahl and T.R. Pedersen
Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged less than65 Versus =65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study)
American Journal of Cardiology, 2009, 103(5), 577-582.
Web of Science® Times Cited: 19 |
Simona Ioana Chisalita, Torbjörn Lindström, Pär Eson Jennersjö, Johan Paulsson, Gunilla Westermark, Anders Olsson and Hans Arnqvist
Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control
Acta Diabetologica, 2009, 46(1), 35-42.
Fulltext  Web of Science® Times Cited: 3 |
Anders Olsson
Is high HDL cholesterol always good?
ANNALS OF MEDICINE, 2009, 41(1), 11-18.
Web of Science® Times Cited: 9 |
Anders Olsson
Nationella riktlinjer för hjärtsjukvård 2008: Lägesbeskrivning eller instrument för förändring?
Läkartidningen, 2008, , 17-18.
|
Milita Crisby and Anders Olsson
Statin i hög dos vid ischemisk stroke minskar risken för ny stroke
Läkartidningen, 2008, 105(48-49), 3541-3543.
|
I. Holme, N.B. Cater, O. Faergeman, J.J.P. Kastelein, Anders G. Olsson, M.J. Tikkanen, Larsen M. Lytken, C. Lindahl and T.R. Pedersen
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL)
Annals of Medicine, 2008, 40(6), 456-464.
|
S. Kinlay, G.G. Schwartz, Anders G. Olsson, N. Rifai, M. Szarek, D.D. Waters, P. Libby and P. Ganz
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study
Arteriosclerosis, Thrombosis and Vascular Biology, 2008, 28(1), 142-147.
Web of Science® Times Cited: 30 |
der Steeg W.A. van, I. Holme, S.M. Boekholdt, M.L. Larsen, C. Lindahl, E.S.G. Stroes, M.J. Tikkanen, N.J. Wareham, O. Faergeman, Anders G Olsson, T.R. Pedersen, K.-T. Khaw and J.J.P. Kastelein
High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk. The IDEAL and EPIC-Norfolk Studies
Journal of the American College of Cardiology, 2008, 51(6), 634-642.
Web of Science® Times Cited: 110 |
D. Maccubbin, H.E. Bays, Anders Olsson, V. Elinoff, A. Elis, Y. Mitchel, W. Sirah, A. Betteridge, R. Reyes, Q. Yu, O. Kuznetsova, C.M. Sisk, R.C. Pasternak and J.F. Paolini
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
International journal of clinical practice (Esher), 2008, 62(12), 1959-1970.
|
John J. P. Kastelein, Wim A. van der Steeg, Ingar Holme, Michael Gaffney, Nilo B. Cater, Philip Barter, Prakash Deedwania, Anders Olsson, S. Matthijs Boekholdt, David A. Demicco, Michael Szarek, John C. LaRosa, Terje R. Pedersen and S Grundy
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Circulation, 2008, 117(23), 3002-3009.
Web of Science® Times Cited: 154 |
J. Karppi, T.H. Rissanen, K. Nyyssonen, J. Kaikkonen, Anders G. Olsson, S. Voutilainen and J.T. Salonen
Effects of astaxanthin supplementation on lipid peroxidation
International Journal for Vitamin and Nutrition Research, 2007, 77(1), .
Web of Science® Times Cited: 16 |
M.J. Tikkanen, G. Jackson, T. Tammela, G. Assmann, A. Palomaki, M. Kupari and Anders Olsson
Erectile dysfunction as a risk factor for coronary heart disease: Implications for prevention
International journal of clinical practice (Esher), 2007, 61(2), 265-268.
Web of Science® Times Cited: 15 |
Andes G. Olsson, G.G. Schwartz, M. Szarek, D. Luo and M.J. Jamieson
Effects of High-Dose Atorvastatin in Patients =65 Years of Age With Acute Coronary Syndrome (from the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering [MIRACL] Study)
American Journal of Cardiology, 2007, 99(5), 632-635.
Web of Science® Times Cited: 27 |
Peter Lindgren, Jennifer Graff, Anders Olsson, Terje J Pedersen and Bengt Jönsson
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
European Heart Journal, 2007, 28(12), 1448-1453.
Web of Science® Times Cited: 26 |
Johnny Nijm, Margareta Kristenson, Anders G. Olsson and Lena Jonasson
Impaired cortisol response to acute stressors in patients with coronary disease: Implications for inflammatory activity
Journal of Internal Medicine, 2007, 262(3), 375-384.
Web of Science® Times Cited: 23 |
T.R. Pedersen, O. Faergeman, J.J.P. Kastelein, Anders Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen and F.S. Bendiksen
High-dose statins and the IDEAL study: Reply
Journal of the American Medical Association (JAMA), 2006, 295(21), 2478-2479.
|
Anders Olsson
The lower the better? Experiences from cardiovascular disease and stroke prevention
Acta Neurologica Scandinavica, 2006, 114(SUPPL. 185), 58-62.
|
Anders G. Olsson
Expanding options with a wider range of rosuvastatin doses
Clinical Therapeutics, 2006, 28(11), 1747-1763.
Web of Science® Times Cited: 3 |
Anders Olsson
Are lower levels of low-density lipoprotein cholesterol beneficial? A review of recent data
Current Atherosclerosis Reports, 2006, 8(5), 382-389.
|
Anders Olsson
PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has comte to nought
Läkartidningen, 2006, 103(35), 2454-2455.
|
Gunilla Hollman, Anders Olsson and Anna-Christina Ek
Disease knowledge and adherence to treatment in patients with familial hypercholesterolemia
Journal of Cardiovascular Nursing, 2006, 21(2), 103-108.
Web of Science® Times Cited: 4 |
Anders Olsson
Lägre LDL-kolesterol är bättre! Sikta på 2mmol/l i sekundärpreventiv behandling
Läkartidningen, 2006, 103, 22-23.
|
T R Pedersen, O Faergeman, JJP Kastelein, Anders Olsson, MJ Tikkanen, I Holme, ML Larsen, FS Bendiksen, C Lindahl, M Szarek and J Tsai
High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction - The IDEAL study: A randomized controlled trial
Journal of the American Medical Association (JAMA), 2005, 294(19), 2437-2445.
Web of Science® Times Cited: 612 |
Bo Ziedén and Anders Olsson
The role of statins in the prevention of ischemic stroke
Current Atherosclerosis Reports, 2005, 7(5), 364-368.
|
G.G. Schwartz, Anders Olsson, M. Szarek and W.J. Sasiela
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial
Diabetes Care, 2005, 28(10), 2508-2513.
Web of Science® Times Cited: 36 |
H. Holdaas, B. Fellstrom, E. Cole, G. Nyberg, Anders G. Olsson, T.R. Pedersen, S. Madsen, C. Gronhagen-Riska, H.-H. Neumayer, B. Maes, P. Ambuhl, A. Hartmann, B. Staffler and A.G. Jardine
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study
American Journal of Transplantation, 2005, 5(12), 2929-2936.
Web of Science® Times Cited: 116 |
Sotirios Tsimikas, Joseph L Witztum, Elisabeth R Miller, William J Sasiela, Michael Szarek, Anders Olsson and Gregory G Schwartz
Letter regarding article by Tsimikas et al, - "High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial" - Response
Acta Obstetricia et Gynecologica Scandinavica, 2005, 111(18), e284-e285.
|
AG Jardine, B Fellstrom, JO Logan, E Cole, G Nyberg, C Gronhagen-Riska, S Madsen, HH Neumayer, B Maes, P Ambuhl, Anders Olsson, T Pedersen and H Holdaas
Cardiovascular risk and renal transplantation: Post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) study
American Journal of Kidney Diseases, 2005, 46(3), 529-536.
Web of Science® Times Cited: 44 |
B. Fellstrom, H. Holdaas, A.G. Jardine, G. Nyberg, C. Gronhagen-Riska, S. Madsen, H.-H. Neumayer, E. Cole, B. Maes, P. Ambuhl, Anders Olsson, B. Staffler and T.R. Pedersen
Risk factors for reaching renal endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) trial
Transplantation, 2005, 79(2), 205-212.
Web of Science® Times Cited: 33 |
Margareta Kristenson, Anders Olsson and Zita Kucinskiene
Good self-rated health is related to psychosocial resources and a strong cortisol response to acute stress: The LiVicordia study of middle-aged men
International Journal of Behavioral Medicine, 2005, 12(3), 153-160.
Web of Science® Times Cited: 15 |
Mark Hirsch, John O´Donnell and Anders Olsson
Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals
International Journal of Cardiology, 2005, 104(3), 251-256.
Web of Science® Times Cited: 7 |
Gerd Assman, Paul Cullen, Jean-Charles Fruchart, Heiner Greten, Marek Naruszewicz, Anders Olsson, Rudolfo Paoletti, Walter Riesen, Monika Stoll, Matti Tikkanen and Arnold Von Eckardstein
Implications of emerging risk factors for therapeutic intervention
NMCD. Nutrition Metabolism and Cardiovascular Diseases, 2005, 15(5), 373-381.
Web of Science® Times Cited: 10 |
Anders Olsson
Kontrollerade kliniska prövningar ger bästa svaret
Läkartidningen, 2005, 102, 2584-2587.
|
Gregory G Schwartz and Anders Olsson
The case for intensive statin therapy after acute coronary syndromes
American Journal of Cardiology, 2005, 96( 5 SUPPL.), .
Web of Science® Times Cited: 15 |
Anders Olsson
TNT-studien ger skjuts i debatten om högdos statiner
Läkartidningen, 2005, 102, 18-19.
|
Anders Olsson, G Schwartz, M Szarek, W Sasiela, M Ezekowitz, P Ganz, M Oliver, D Waters and A Zeiher
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: Results from the MIRACL trial
European Heart Journal, 2005, 26(9), 890-896.
Web of Science® Times Cited: 72 |
Anders Olsson
Risk factors for reaching renal endpoints in the assessment of lescol in renal transplantation (ALERT) trial
Transplantation, 2005, 792, 205-212.
Web of Science® Times Cited: 33 |
Anders Olsson
A to Z
Information från Läkemedelsverket, 2005, 1, 16-17.
|
Anders Olsson
Prove-it
Information från Läkemedelsverket, 2005, 1, 14-15.
|
Anders Olsson
Det metabola syndromet och dess konsekvenser
Incitament, 2005, 1, 25-27.
|
Johnny Nijm, Anders Wikby, Andrea Tompa, Anders G Olsson and Lena Jonasson
Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease
American Journal of Cardiology, 2005, 95(4), 452-456.
Web of Science® Times Cited: 57 |
B Fellstrom, H Holdaas, AG Jardine, I Holme, G Nyberg, P Fauchald, C Gronhagen-Riska, S Madsen, HH Neumayer, E Cole, B Maes, P Ambuhl, Anders Olsson, A Hartmann, JO Logan and TR Pedersen
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial
Kidney International, 2004, 66(4), 1549-1555.
Web of Science® Times Cited: 59 |
T.R. Pedersen, O. Faergeman, J.J.P. Kastelein, Anders Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen, F.S. Bendiksen, C. Lindahl and G. Palmer
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study
American Journal of Cardiology, 2004, 94(6), 720-724.
Web of Science® Times Cited: 30 |
Anders Olsson, Roman Casciano, Lee Stern and Per Svengren
A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden
International Journal of Cardiology, 2004, 96(1), 51-57.
Web of Science® Times Cited: 7 |
Wei Li, Anna Hellsten, Leif Jacobsson, Henrik Blomqvist, Anders Olsson and Xi Ming Yuan
Alpha-tocopherol and astaxanthin decrease macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits
Journal of Molecular and Cellular Cardiology, 2004, 37(5), 969-978.
Web of Science® Times Cited: 30 |
Anders Olsson, A Jardine, H Holdaas, B Fellström, E Cole, G Nyberg, C Grönhagen-Riska, S Madsen, H-H Neumayer and B Maes
Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: Post-hoc subgroup analyses of the ALERT study
American Journal of Transplantation, 2004, 4(6), 988-995.
Web of Science® Times Cited: 61 |
Gunilla Hollman, Anna-Christina Ek, Anders Olsson and Carina Berterö
The meaning of quality of life among patients with familial hypercholesterolemia
Journal of Cardiovascular Nursing, 2004, 19(4), 243-250.
|
Gunilla Hollman, Anna-Christina Ek and Anders Olsson
Only one of four patients with familial hypercholesterolaemia reach cholesterol treatment goals in primary prevention
Journal of Internal Medicine, 2004, 256(2), 176-177.
Web of Science® Times Cited: 2 |
S Tsimikas, JL Witztum, ER Miller, WJ Sasiela, M Szarek, Anders Olsson and GG Schwartz
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial
Circulation, 2004, 110(11), 1406-1412.
Web of Science® Times Cited: 83 |
Ulf Stenestrand and Anders Olsson
Ju lägre LDL-kolesterol destö bättre!
Läkartidningen, 2004, 101, 3246-3247.
|
Anders Olsson
Apolipoprotein A-I kan vara ettnytt verktyg i behandlingen av ateroskleros
Läkartidningen, 2004, 101, 1196-1197.
|
Anders Olsson
Replik: Att följa Ravnskovs råd skulle innebära återgång i ökad dödlighet och sjuklighet. Slutreplik
Läkartidningen, 2004, 101, 1218-1222.
|
Anders Olsson
Psychosocial factors and coronary heart disease
Current Atherosclerosis Reports, 2004, 6(1), .
|
Anders Olsson
Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in teh Scandinavian Simvastatin Survival Study
Atherosclerosis, 2004, 5, 99-106.
|
Anders Olsson
The importance of the emergence of statins toa lipidologist - clinician: a personal perspective
Atherosclerosis, 2004, 5, 27-28.
Web of Science® Times Cited: 1 |
S Lind, Anders Olsson, M Eriksson, M Rudling, G Eggertsen and B Angelin
Autosomal recessive hypercholesterolaemia: Normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment
Journal of Internal Medicine, 2004, 256(5), 406-412.
Web of Science® Times Cited: 19 |
S Kinlay, G Schwartz, Anders Olsson, N Rifai, W Sasiela, M Szarek, P Ganz and P Libby
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study
Circulation, 2004, 110(4), 386-391.
Web of Science® Times Cited: 100 |
Lena Jonasson, A. Wikby and Anders Olsson
Low serum ß-carotene reflects immune activation in patients with coronary artery disease
NMCD. Nutrition Metabolism and Cardiovascular Diseases, 2003, 13(3), 120-125.
Web of Science® Times Cited: 7 |
H. Holdaas, B. Fellstrom, A.G. Jardine, I. Holme, G. Nyberg, P. Fauchald, C. Gronhagen-Riska, S. Madsen, H.-H. Neumayer, E. Cole, B. Maes, P. Ambuhl, Anders Olsson, A. Hartmann, D.O. Solbu and T.R. Pedersen
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial
The Lancet, 2003, 361(9374), 2024-2031.
Web of Science® Times Cited: 393 |
Anders Olsson
Vilka målvärden ska vi ha för lipidsänkande behandling?
Information från Läkemedelsverket, 2003, 4, 37-42.
|
Anders Olsson
Statins: how far have we come? A review of rosuvastatin.
International journal of clinical practice (Esher), 2003, 137, 15-25.
|
S Kinlay, G Schwartz, Anders Olsson, N Rifai, S Leslie, WJ Sasiela, M Szarek, P Libby and P Ganz
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study
Circulation, 2003, 108(13), 1560-1566.
Web of Science® Times Cited: 214 |
Anders Olsson, M Eriksson, O Johnson, T Kjellström, J Lanke, M Lytken Larsen, T Pedersen, MJ Tikkanen and O Wiklund
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: The Treat-to-Target (3T) Study
Clinical Therapeutics, 2003, 25(1), 119-138.
Web of Science® Times Cited: 23 |
Gunilla Hollman, Anders Olsson and Anna-Christina Ek
Familial hypercholesterolaemia and quality of life in family members
Preventive Medicine, 2003, 36(5), 569-574.
Web of Science® Times Cited: 9 |
Henrik Blomqvist and Anders Olsson
Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia
Scandinavian Journal of Clinical and Laboratory Investigation, 2003, 63(7-8), 513-519.
Web of Science® Times Cited: 3 |
Jane Wigren, Sailesh Surapureddi, Anders Olsson, C. K. Glass, Sven Hammarström and Mats Söderström
Differential recruitment of the coactivator proteins CREB-binding protein and steroid receptor coactivator-1 to peroxisome proliferator-activated receptor gamma/9-cis-retinoic acid receptor heterodimers by ligands present in oxidized low-density lipoprotein
Journal of Endocrinology, 2003, 177(2), 207-214.
Web of Science® Times Cited: 11 |
C Packard and Anders Olsson
Management of hypercholesterol - aemia in the patient with diabetes
International journal of clinical practice (Esher), 2002, , 27-32.
Web of Science® Times Cited: 1 |
B Zieden, A Kaminskas, M Kristenson, Anders Olsson and Z Kucinskiene
Long chain polyunsaturated fatty acids may account for higher low-density lipoprotein oxidation susceptibility in Lithuanian compared to Swedish men
Scandinavian Journal of Clinical and Laboratory Investigation, 2002, 62(4), 307-314.
Web of Science® Times Cited: 8 |
Anders Olsson, F McTaggart and AG Raza
Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor
Cardiovascular Drug Reviews, 2002, 20(4), 303-328.
Web of Science® Times Cited: 63 |
Anders Olsson
Rosuvastatin - A viewpoint by Anders G Olsson
Drugs : international journal of current therapeutics and applied pharmacology reviews ..., 2002, 62, 2086-2086.
|
Anders Olsson
Nya rön talar mot statinbehandling vid akut kranskärlssjukdom. Men vanskligt att bedöma behandlingseffekt utifrån observationella studier.
Läkartidningen, 2002, 99, 4348-4349.
|
L Jonasson, C Linderfalk, J Olsson, A Wikby and Anders Olsson
Systemic T-cell activation in stable angina pectoris
American Journal of Cardiology, 2002, 89(6), 754-756.
Web of Science® Times Cited: 14 |
Anders Olsson and GG Schwartz
Early initiation of treatment with statins in acute coronary syndromes
Annals of Medicine, 2002, 34(1), 37-41.
Web of Science® Times Cited: 8 |
DD Waters, GG Schwartz, Anders Olsson, A Zeiher, MF Oliver, P Ganz, M Ezekowitz, BR Chaitman, SJ Leslie and T Stern
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy
Circulation, 2002, 106(13), 1690-1695.
Web of Science® Times Cited: 115 |
Anders Olsson, Helge Istad, Olavi Luurila, Leiv Ose, Steen Stender, Jaakko Tuomilehto, Olov Wiklund, Harry Southworth, John Pears and J W Wilpshaar
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
American Heart Journal, 2002, 144(6), 1044-1051.
Web of Science® Times Cited: 105 |
Anders Olsson, G G Schwartz, Lena Jonasson and C Linderfalk
Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
Acta Physiologica Scandinavica, 2002, 176(2), 147-150.
Web of Science® Times Cited: 15 |
GG Schwartz and Anders Olsson
Lipid lowering in acute coronary syndromes: New evidence, new questions
Current Atherosclerosis Reports, 2002, 4, .
|
Gunilla Hollman, Mats Gullberg, Anna-Christina Ek, Mats Eriksson and Anders G. Olsson
Quality of life in patients with familial hypercholesterolaemia
Journal of Internal Medicine, 2002, 251(4), 331-337.
Web of Science® Times Cited: 13 |
Bertil Ekman, Torbjörn Lindström, Fredrik Nyström, Anders Olsson, Göran Toss and Hans Arnqvist
A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults
European Journal of Endocrinology, 2002, 147(1), 49-57.
Web of Science® Times Cited: 11 |
Anders Olsson
A new statin: A new standard
Clinical Cardiology, 2001, 24(8), 18-23.
Web of Science® Times Cited: 4 |
Anders Olsson, J. Pears, J. McKellar, J. Mizan and A. Raza
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
American Journal of Cardiology, 2001, 88(5), 504-508.
Web of Science® Times Cited: 137 |
Anders Olsson
Statiner skall sättas in akut på sjukhus. Livsstilsrelaterade åtgärder vid kranskärlssjukdom får dock inte glömmas.
Läkartidningen, 2001, 98, 2704-2706.
|
Anders Olsson
Statin therapy and reductions in low-density lipoprotein cholesterol: Initial clinical data on the potent new statin rosuvastatin
American Journal of Cardiology, 2001, 87(5 SUPPL. 1), .
Web of Science® Times Cited: 33 |
D Waters, GG Schwartz and Anders Olsson
The myocardial ischemia reduction with acute cholesterol lowering (MIRACL) trial: A new frontier for statins?
Current Controlled Trials in Cardiovascular Medicine, 2001, 2(3), 111-114.
Web of Science® Times Cited: 14 |
CM Ballantyne, Anders Olsson, TJ Cook, MF Mercuri, TR Pedersen and J Kjekshus
Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S
Circulation, 2001, 104(25), 3046-3051.
Web of Science® Times Cited: 202 |
Anders Olsson
A new statin: A new standard
American Journal of Managed Care, 2001, 7, 152-154.
Web of Science® Times Cited: 3 |
Gregory Schwartz, Anders Olsson, Michael Ezekowitz, Peter Ganz, Michael Oliver, David Waters, Andreas Zeither, Bernard Chaitman, Sally Leslie and Theresa Stern
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial.
Journal of the American Medical Association (JAMA), 2001, 285, 1711-1718.
Web of Science® Times Cited: 1293 |
Hallvard Holdaas, Bengt Fellström, Ingar Holme, Gudrun Nyberg, Per Fauchald, Alan Jardine, Carola Grönhagen-Riska, Sören Madsen, Hans-Hellmut Neymayer, Edward Cole, Bart Meas, Weinreich Thomas, Anders Olsson, Terje Pedersen, Renée Benghozi and Anders Hartmann
Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (assessment of Lescol in renal tranplantion) study design and baseline data
Journal of Cardiovascular Risk, 2001, 8, 63-71.
Web of Science® Times Cited: 56 |
Anders Olsson, P Pauciullo, V Soska, C Luley, RE Pieters, G Broda and B Palacios
Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: A randomized trial
Clinical Therapeutics, 2001, 23(1), 45-61.
Web of Science® Times Cited: 15 |
L Ose, O Luurila, J Eriksson, Anders Olsson, H Lithell and B Widgren
Cerivastatin gender effect: Sub-analyses of results from a multinational, randomised, double-blind study
Current Medical Research and Opinion, 2000, 16(2), 80-87.
Web of Science® Times Cited: 9 |
T.R. Pedersen, L. Wilhelmsen, O. Faergeman, T.E. Strandberg, G. Thorgeirsson, L. Troedsson, J. Kristianson, K. Berg, T.J. Cook, T. Haghfelt, J. Kjekshus, T. Miettinen, Anders Olsson, K. Pyorala and H. Wedel
Follow-up study of patients randomized in The Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering
American Journal of Cardiology, 2000, 86(3), 257-262.
Web of Science® Times Cited: 156 |
Anders Olsson
H÷gt kolesterolvΣrde diskrimineras i nya behandlingsrekommendationer
Läkartidningen, 2000, 97(16), 1995-1996.
|
Anders Olsson
Lipidprevention av kranskärlssjukdom utan sänkning av LDL-kolesterol.
Läkartidningen, 2000, 97, 1368-1370.
|
Niels Erik Nielsen, Anders Olsson and Eva Swahn
Plasma lipoprotein particle concentrations in postmenopausal women with unstable coronary artery disease: Analysis of diagnostic accuracy using receiver operating characteristics
Journal of Internal Medicine, 2000, 247(1), 43-52.
Web of Science® Times Cited: 7 |
Margareta Kristenson, Claes Lassvik, Björn Bergdahl, Z Kucinskiene, L Aizieniene, Bo Ziedén, Liselott Schäfer Elinder and Anders Olsson
Ultrasound determined carotid and femoral atherosclerosis in Lithuanian and Swedish men: The LiVicordia study
Atherosclerosis, 2000, 151(2), 501-508.
Web of Science® Times Cited: 9 |
Anders Olsson
Den nya kolesteroldebatten: Är lägst bäst?
Läkartidningen, 1999, 96, 648-652.
|
Anders Olsson
En ny sorts studie behövs.
Läkartidningen, 1999, 96, 1949-1949.
|
J Mölgaard, S Wärjestam-Elf and Anders Olsson
Efficacy and safety of simvastatin for highrisk hypercholseterolemia.
American Journal of Cardiology, 1999, 83, 1043-1048.
|
Torbjörn Lindström, Fredrik Nyström, Anders Olsson, Hans Arnqvist and A-M Ottosson
The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with type2 diabetes mellitus.
Diabetic Medicine, 1999, 16, 820-826.
|
Bo Zidén, A Kaminkas, Margareta Kristensson, Z Kucinskiene, B Vessby, Anders Olsson and U Diczfaluzy
Increased plasma 7B-hydroxycholesterol concentrations in a population with high risk for cardiovascular disease.
Arteriosclerosis, Thrombosis and Vascular Biology, 1999, 19, 967-971.
|
A Kaminskas, Bo Ziedén, B Elving, Margareta Kristenson, A Abaravicius, Björn Bergdahl, Anders Olsson and Z Kucinskiene
Adipose tissue fatty acids in men from two populations with different cardiovascular risk - the LiVicordia study.
Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 227-232.
|
Wei Li, Xi Ming Yuan, Anders Olsson and Ulf Brunk
Uptake of Oxidized LDL by Macrophages Results in Partial Lysosomal Enzyme Inactivation and Relocation
Arteriosclerosis, Thrombosis and Vascular Biology, 1998, 18(2), 177-84.
|
XiMing Yuan, Wei Li, Anders Olsson and Ulf Brunk
The toxicity to macrophages of oxidized low-density lipoprotein is mediated through lysosomal damage
Atherosclerosis, 1997, 133(2), 153-61.
|
Anders Olsson and XiMing Yuan
Antioxidants in the prevention of atherosclerosis
Current Opinion in Lipidology, 1996, 7(6), 374-80.
|
XiMing Yuan, Anders Olsson and Ulf Brunk
Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis
Atherosclerosis, 1996, 124(1), 61-73.
|
XiMing Yuan, Ulf Brunk and Anders Olsson
Effects of iron- and hemoglobin-loaded human monocyte-derived macrophages on oxidation and uptake of LDL
Arteriosclerosis, Thrombosis and Vascular Biology, 1995, 15(9), 1345-51.
|
Leif S. Jacobsson, Karin Persson, Gunnar Aberg, Rolf G. G. Andersson, Bengt E. Karlberg and Anders G. Olsson
Antiatherosclerotic Effects of the Angiotensin-Converting Enzyme Inhibitors Captopril and Fosinopril in Hypercholesterolemic Minipigs
Journal of Cardiovascular Pharmacology, 1994, 24(4), 670-677.
|
Books
Chapters in Books
Conference Articles
Fabian Chen, Darbie Maccubbin, Jennifer Weimer Anderson, Christine McCrary Sisk, Uma Kher, Anders Olsson and Harold E Bays
Following Stable Therapy with Extended Release Niacin/Laropiprant, Continued Extended Release Niacin/Laropiprant Use Reduced Flushing versus Extended Release Niacin Alone in Dyslipidemic Patients in CIRCULATION, vol 124, issue 21, pp
CIRCULATION, 2011.
|
Matti J. Tikkanen, Rana Fayyad, Rachel Laskey, Ingar Holme, Ole Faergeman, Anders Olsson, Christina Lindahl, John J. Kastelein, Mogens Lytken Larsen and Terje R. Pedersen
Among CHD Patients in the IDEAL Study, Those with Elevated Levels of Alanine Aminotransferase at Baseline Had a Lower Rate of Major Coronary Events in CIRCULATION, vol 124, issue 21, pp
CIRCULATION, 2011.
|
R L Ohsfeldt, Anders Olsson, M M Jensen, S K Gandhi and T Paulsson
The cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality - a swedish economic evaluation of the JUPITER trial in EUROPEAN HEART JOURNAL, vol 31, issue , pp 225-225
EUROPEAN HEART JOURNAL, 2010.
|
Anders Olsson, C Lindahl, I Holme, R Fayyad, O Faergeman, J Kastelein, M Tikkanen, M Lytken Larsen and T Pedersen
CORONARY PATIENTS REACHING LDL-CHOLESTEROL andlt; 2.0 mmol/L HAVE THE LOWEST RISK OF CARDIOVASCULAR EVENTS DURING STATIN TREATMENT: THE IDEAL STUDY in ATHEROSCLEROSIS SUPPLEMENTS, vol 11, issue 2, pp 53-53
ATHEROSCLEROSIS SUPPLEMENTS, 2010.
|
Anders Olsson, C Lindahl, R Fayyad, S Bhatia and I Holme
CAN LIPID/APOLIPOPROTEIN FACTORS ACCOUNT FOR RESIDUAL RISK IN PATIENTS ATTAINING CURRENT LDL-C TARGETS?
ATHEROSCLEROSIS SUPPLEMENTS, 2009.
|
Johnny Nijm, Anders Olsson and Lena Jonasson
Impaired cortisol response in patients with coronary artery disease - relation to inflammatory activity
Scandinavian Cardiovascular Journal,2006, 2006.
|
Peter Garvin, Lena Jonasson, Margareta Kristenson, Johnny Nijm, Lennart Nilsson and Anders Olsson
Psychosocial factors in atherosclerosis
XIV International Symposium on Atherosclerosis,2006, 2006.
|
Johnny Nijm, Anders Olsson and Lena Jonasson
Impaired cortisol response in patients with coronary artery disease - relation to inflammatory activity
XIV International Symposium on Atherosclerosis,2006, 2006.
|
P Cherfan, Anders Olsson and Lena Jonasson
Effects of simvastatin on human t-cells in vivo
European Atherosclerosis Society Congress,2005, 2005.
|
Anders Olsson, P Cherfan, Henrik Blomqvist and Lena Jonasson
Serum adiponectin - its association with inflammation and statin treatment
EAS Congress,2005, 2005.
|
Anders Olsson and C Packard
New global standards in lipid lowering: a review of emerging evidence and concepts.
Int J Clin Practice,2002, 2002.
|
S Hellerström, M Malmgren, Anders Olsson, A Gustafsson and Göran Granerus
Evaluation of radiation doses to medical staff working with 18 F-FDG gamma camera PET studies.
World J Nucl Med,2002, 2002.
|
Gunilla Hollman, Anders Olsson and Anna-Christina Ek
Quality of life in non affected family members of familial hypercholesterolemia families
Konferens Familjefokuserad omvårdnad, Kalmar,2002, 2002.
|
O Nygard, H Refsum, J Kjekshus, PM Ueland, SE Vollset, K Berg, Anders Olsson, TJ Cook and TR Pedersen
Total homocysteine levels predicts major coronary events and mortality in simvastatin treated patients of 4S
Circulation, 2001.
|
D Waters, GG Schwartz, Anders Olsson, MF Oliver, P Ganz, MD Ezekowitz, S Leslie and T Stern
Stroke reduction with atorvastatin in acute coronary syndromes: Results of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) trial
Circulation, 2001.
|
Gunilla Hollman, Anna-Christina Ek, Mats Eriksson and Anders Olsson
Quality of life in familial hypercholesterolaemia families.
72nd European atherosclerosis society congress, Glasgow, Storbritannien,2001, 2001.
|
Anders Olsson, JS Pears, J McKellar, RJ Caplan and A Raza
ZD4522 - a new HMG-CoA reductase inhibitor - causes rapid and profound reductions in plasma LDL-C levels in patients with primary hypercholesterolaemia
European Heart Journal, 2000.
|
L Jonasson, C Linderfalk, A Wikby and Anders Olsson
T lymphocyte activation in stable angina pectoris: The influence of statin treatment.
Circulation, 2000.
|
* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.
Ph.D., Lic. Theses
